APA (7th ed.) Citation

Cherifi, F., Cabel, L., Bousrih, C., Volant, E., Dalenc, F., Mery, B., . . . Emile, G. (2024). 238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort. Annals of Oncology, 35, S312. https://doi.org/10.1016/j.annonc.2024.08.181

Chicago Style (17th ed.) Citation

Cherifi, F., et al. "238MO PROMENADE: PembROlizuMab for Early Triple Negative ER-low Breast CaNcer, ReAl WorlD FrEnch Cohort." Annals of Oncology 35 (2024): S312. https://doi.org/10.1016/j.annonc.2024.08.181.

MLA (9th ed.) Citation

Cherifi, F., et al. "238MO PROMENADE: PembROlizuMab for Early Triple Negative ER-low Breast CaNcer, ReAl WorlD FrEnch Cohort." Annals of Oncology, vol. 35, 2024, p. S312, https://doi.org/10.1016/j.annonc.2024.08.181.